ESTRO PT 2018

 Primary endpoint: 2 Y EPIC moderate+ bother from bowel urgency or frequency  Secondary endpoints: FFBP, incidence of GI and GU toxicities requiring intervention  Outcome comparison between black& white  Comparison of other EPIC QOL parameters  Collection of demographic & gene sequences  Minority participation enhancement program  Embedded Fractionation RCT PTCOG GU Subcommittee Workshop Prospective Comparison of Outcomes in Prostate Cancer Patients Treated with Photons or Protons